Xponance Inc. Acquires 2,025 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Xponance Inc. increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 14.4% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 16,097 shares of the company’s stock after purchasing an additional 2,025 shares during the period. Xponance Inc.’s holdings in Apellis Pharmaceuticals were worth $352,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after buying an additional 758 shares in the last quarter. Signaturefd LLC increased its holdings in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after buying an additional 918 shares in the last quarter. GF Fund Management CO. LTD. increased its holdings in Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after buying an additional 573 shares in the last quarter. Covestor Ltd boosted its position in Apellis Pharmaceuticals by 1,819.2% in the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after purchasing an additional 3,784 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Apellis Pharmaceuticals by 89.0% in the fourth quarter. Russell Investments Group Ltd. now owns 6,107 shares of the company’s stock worth $195,000 after purchasing an additional 2,876 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Down 2.8%

APLS stock opened at $19.47 on Friday. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $41.94. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76. The stock has a market cap of $2.45 billion, a P/E ratio of -10.88 and a beta of 0.67. The business’s 50-day moving average price is $18.23 and its 200-day moving average price is $22.64.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The company had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $197.61 million. During the same period in the previous year, the firm earned ($0.54) earnings per share. The firm’s quarterly revenue was down 3.2% on a year-over-year basis. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $19.55, for a total value of $97,750.00. Following the transaction, the general counsel directly owned 128,730 shares of the company’s stock, valued at approximately $2,516,671.50. The trade was a 3.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cedric Francois sold 137,465 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $20.19, for a total value of $2,775,418.35. Following the completion of the transaction, the chief executive officer directly owned 343,433 shares in the company, valued at approximately $6,933,912.27. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 169,090 shares of company stock worth $3,403,832. 6.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have issued reports on APLS shares. Cantor Fitzgerald started coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $44.00 target price on the stock. Morgan Stanley raised their target price on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 2nd. Scotiabank dropped their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research report on Thursday, May 8th. Royal Bank Of Canada dropped their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research report on Thursday, May 8th. Finally, Raymond James Financial cut Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and dropped their target price for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Nine research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).